297 related articles for article (PubMed ID: 29491296)
21. Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.
Kawazoe M; Kaneko K; Yamada Z; Masuoka S; Mizutani S; Yamada S; Shikano K; Sato H; Kaburaki M; Muraoka S; Kawai S; Nanki T
Clin Rheumatol; 2019 Jun; 38(6):1571-1578. PubMed ID: 30778862
[TBL] [Abstract][Full Text] [Related]
22. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.
Sahin GM; Sahin S; Kiziltas S; Masatlioglu S; Oguz F; Ergin H
Ren Fail; 2008; 30(9):865-9. PubMed ID: 18925525
[TBL] [Abstract][Full Text] [Related]
23. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
Jesus D; Rodrigues M; da Silva JAP; Inês L
Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
[TBL] [Abstract][Full Text] [Related]
24. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis.
Koo HS; Kim YC; Lee SW; Kim DK; Oh KH; Joo KW; Kim YS; Ahn C; Han JS; Kim S; Chin HJ
Lupus; 2011 Nov; 20(13):1442-9. PubMed ID: 21951944
[TBL] [Abstract][Full Text] [Related]
25. Lupus nephritis: treatment with mycophenolate mofetil.
Kapitsinou PP; Boletis JN; Skopouli FN; Boki KA; Moutsopoulos HM
Rheumatology (Oxford); 2004 Mar; 43(3):377-80. PubMed ID: 14963204
[TBL] [Abstract][Full Text] [Related]
26. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
[TBL] [Abstract][Full Text] [Related]
27. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis.
Moore RA; Derry S
Arthritis Res Ther; 2006; 8(6):R182. PubMed ID: 17163990
[TBL] [Abstract][Full Text] [Related]
28. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.
Li X; Ren H; Zhang Q; Zhang W; Wu X; Xu Y; Shen P; Chen N
Nephrol Dial Transplant; 2012 Apr; 27(4):1467-72. PubMed ID: 21917733
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
Choi CB; Won S; Bae SC
Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
[TBL] [Abstract][Full Text] [Related]
30. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis.
Walsh M; James M; Jayne D; Tonelli M; Manns BJ; Hemmelgarn BR
Clin J Am Soc Nephrol; 2007 Sep; 2(5):968-75. PubMed ID: 17702723
[TBL] [Abstract][Full Text] [Related]
31. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide.
Glicklich D; Acharya A
Am J Kidney Dis; 1998 Aug; 32(2):318-22. PubMed ID: 9708620
[TBL] [Abstract][Full Text] [Related]
32. Sequential therapies for proliferative lupus nephritis.
Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
[TBL] [Abstract][Full Text] [Related]
33. Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review.
Margiotta DPE; Basta F; Batani V; Afeltra A
BMC Nephrol; 2018 Mar; 19(1):54. PubMed ID: 29514612
[TBL] [Abstract][Full Text] [Related]
34. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
[TBL] [Abstract][Full Text] [Related]
35. [Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil].
Sixdorf U; Bauer H; Märker-Hermann E
Dtsch Med Wochenschr; 2006 Oct; 131(41):2266-9. PubMed ID: 17036267
[TBL] [Abstract][Full Text] [Related]
36. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
Wang J; Hu W; Xie H; Zhang H; Chen H; Zeng C; Liu Z; Li L
Lupus; 2007; 16(9):707-12. PubMed ID: 17728363
[TBL] [Abstract][Full Text] [Related]
37. Long-term renal survival of paediatric patients with lupus nephritis.
Demir S; Gülhan B; Özen S; Çeleğen K; Batu ED; Taş N; Orhan D; Bilginer Y; Düzova A; Ozaltin F; Topaloğlu R
Nephrol Dial Transplant; 2022 May; 37(6):1069-1077. PubMed ID: 33826705
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis.
Lanata CM; Mahmood T; Fine DM; Petri M
Lupus; 2010 Jul; 19(8):935-40. PubMed ID: 20388722
[TBL] [Abstract][Full Text] [Related]
39. Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study.
Tselios K; Gladman DD; Su J; Urowitz MB
J Rheumatol; 2016 Mar; 43(3):552-8. PubMed ID: 26773121
[TBL] [Abstract][Full Text] [Related]
40. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis.
Radhakrishnan J; Moutzouris DA; Ginzler EM; Solomons N; Siempos II; Appel GB
Kidney Int; 2010 Jan; 77(2):152-60. PubMed ID: 19890271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
